€30m raised for first-in-class in vivo cell reprogramming platform
Drug Discovery World
MARCH 19, 2024
Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. The post €30m raised for first-in-class in vivo cell reprogramming platform appeared first on Drug Discovery World (DDW). This financing also follows a strong pre-clinical package providing PoC for AT-108.
Let's personalize your content